Please login to the form below

Not currently logged in
Email:
Password:

oseltamivir

This page shows the latest oseltamivir news and features for those working in and with pharma, biotech and healthcare.

Roche’s Xofluza pill wins FDA approval for post-exposure flu prevention

Roche’s Xofluza pill wins FDA approval for post-exposure flu prevention

It has already been shown to be effective against a wide range of flu viruses, including those resistant to Roche’s now off-patent and former blockbuster flu treatment, Tamiflu (oseltamivir).

Latest news

  • Roche scores another FDA approval for Xofluza Roche scores another FDA approval for Xofluza

    oseltamivr. The approval was based on results from Roche’s phase 3 CAPSTONE-2 trial of Xofluza, compared to oseltamivir or placebo, in people aged 12 or over, who met the ... However, similar efficacy results were seen between Xofluza and oseltamivir

  • UK bans some drug exports to preserve NHS stocks UK bans some drug exports to preserve NHS stocks

    It applies mainly to hormone replacement therapies but also includes all adrenaline pens, hepatitis B vaccines and the influenza drug oseltamivir, sold by Roche as Tamiflu, amongst other drugs.

  • Roche’s flu drug Xofluza scores phase 3 primary endpoint Roche’s flu drug Xofluza scores phase 3 primary endpoint

    It has already been shown to be effective against a wide range of flu viruses, including those resistant to Roche’s now off-patent and former blockbuster flu treatment, Tamiflu (oseltamivir). ... Roche is keen to produce more evidence of the

  • Roche’s new flu pill Xofluza approved in US Roche’s new flu pill Xofluza approved in US

    Xofluza significantly reduced the duration of flu symptoms compared to placebo, and demonstrated similar efficacy compared to oseltamivir. ... Analysts say the new treatment will have to generate more evidence of significant benefits in these high risk

  • Encouraging data for Roche flu drug ahead of FDA decision Encouraging data for Roche flu drug ahead of FDA decision

    Analysts say the new treatment will have to generate more evidence of significant benefits in these high risk groups in order for healthcare systems to switch away from generic oseltamivir.

More from news
Approximately 0 fully matching, plus 35 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Are you ready for the digital health revolution?
In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...

Infographics